Search

Displaying results 2771 - 2780 of 7452 in total
  1. Drug

    Isoxaflutole

    go.drugbank.com/drugs/DB12938
    ApprovedWithdrawn

    Balance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.

  2. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy … [L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349]

  3. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval. … On December 17, 2025, the FDA granted regular approval to rucaparib for adults with a deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with

  4. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

  5. Drug

    Sorafenib

    go.drugbank.com/drugs/DB00398
    ApprovedInvestigational

    [A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma

  6. Drug

    Nitrite

    go.drugbank.com/drugs/DB12529
    ApprovedWithdrawn

    Nitrite is under investigation for the treatment of Heart Failure.

  7. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. ...

  8. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)

  9. Drug

    Alcaftadine

    go.drugbank.com/drugs/DB06766
    Approved

    Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.

  10. Drug

    Dimethyltryptamine

    go.drugbank.com/drugs/DB01488
    IllicitInvestigational

    An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. It apparently acts as an agonist at some types of seroton...